AU3406489A - Use of and agent for reducing side effects of tnf - Google Patents

Use of and agent for reducing side effects of tnf

Info

Publication number
AU3406489A
AU3406489A AU34064/89A AU3406489A AU3406489A AU 3406489 A AU3406489 A AU 3406489A AU 34064/89 A AU34064/89 A AU 34064/89A AU 3406489 A AU3406489 A AU 3406489A AU 3406489 A AU3406489 A AU 3406489A
Authority
AU
Australia
Prior art keywords
side effects
tnf
agent
reducing side
tnfs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU34064/89A
Other versions
AU614607B2 (en
Inventor
Hubert Heuer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of AU3406489A publication Critical patent/AU3406489A/en
Application granted granted Critical
Publication of AU614607B2 publication Critical patent/AU614607B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Paper (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Concomitant administration of TNFs with a PAF antagonist allows the unwanted side effects of the TNFs to be reduced and the therapeutic index of the TNFs to be increased.
AU34064/89A 1988-05-11 1989-05-05 Use of and agent for reducing side effects of tnf Ceased AU614607B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3816169A DE3816169A1 (en) 1988-05-11 1988-05-11 USE AND AGENT FOR REDUCING THE SIDE EFFECTS OF TNF
DE3816169 1988-05-11

Publications (2)

Publication Number Publication Date
AU3406489A true AU3406489A (en) 1989-11-16
AU614607B2 AU614607B2 (en) 1991-09-05

Family

ID=6354207

Family Applications (1)

Application Number Title Priority Date Filing Date
AU34064/89A Ceased AU614607B2 (en) 1988-05-11 1989-05-05 Use of and agent for reducing side effects of tnf

Country Status (13)

Country Link
EP (1) EP0341558B1 (en)
JP (1) JP2709139B2 (en)
KR (1) KR900017592A (en)
AT (1) ATE78695T1 (en)
AU (1) AU614607B2 (en)
CA (1) CA1336825C (en)
DE (2) DE3816169A1 (en)
DK (1) DK220789A (en)
ES (1) ES2042864T3 (en)
GR (1) GR3005387T3 (en)
HU (1) HUT52381A (en)
IL (1) IL90206A0 (en)
ZA (1) ZA893259B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU613672B2 (en) * 1987-10-20 1991-08-08 Korth, Ruth-Maria Dr. Treatment of diseases with paf-acether-antagonists and procedure for determining their efficacy

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8926611D0 (en) * 1989-11-24 1990-01-17 Xenova Ltd Compound and its use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002632A1 (en) * 1986-10-16 1988-04-21 President And Fellows Of Harvard College Combinations of tumor necrosis factors and anti-inflammatory agents and methods for treating malignant and non-malignant diseases

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU613672B2 (en) * 1987-10-20 1991-08-08 Korth, Ruth-Maria Dr. Treatment of diseases with paf-acether-antagonists and procedure for determining their efficacy

Also Published As

Publication number Publication date
DK220789A (en) 1989-11-12
GR3005387T3 (en) 1993-05-24
EP0341558A2 (en) 1989-11-15
EP0341558B1 (en) 1992-07-29
ES2042864T3 (en) 1993-12-16
CA1336825C (en) 1995-08-29
ZA893259B (en) 1991-01-30
JPH0276825A (en) 1990-03-16
DE3816169A1 (en) 1989-11-23
KR900017592A (en) 1990-12-19
IL90206A0 (en) 1989-12-15
EP0341558A3 (en) 1990-05-09
ATE78695T1 (en) 1992-08-15
DK220789D0 (en) 1989-05-05
HUT52381A (en) 1990-07-28
DE58901920D1 (en) 1992-09-03
AU614607B2 (en) 1991-09-05
JP2709139B2 (en) 1998-02-04

Similar Documents

Publication Publication Date Title
AU4519089A (en) Device for aiding in preparation of intravenous therapy
AU4741790A (en) Syringe adapted to prevent needle sticks
GB2221390B (en) Niacin-containing composition and its therapeutic use
AU6717687A (en) Arrangement in injection syringe for use once only
AU6477386A (en) Table to be attached at the rear of a chair back
GR880100551A (en) Sanitary nappy with flaps having an oblique groove
AU2260488A (en) Multi-lumen epidural-spinal needle
GB8802349D0 (en) Ampoule with luer
AU3273689A (en) Diagnosis of chronic myelogenous leukemia
AU623147B2 (en) Compounds for use in medicine
AU2726088A (en) Ampule for controlled administration of beneficial agent
ZA898201B (en) Gestodene-containing agent for transdermal administration
AU2297388A (en) Therapeutic agents
AU2049388A (en) Transdermal administration using benzyl alcohol
MY103872A (en) 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function.
AU4515989A (en) Warning device in the use of venous drip feeds
AU3406489A (en) Use of and agent for reducing side effects of tnf
PH31582A (en) Glycoslated cytokins.
AU2908389A (en) Device for administering medicaments by atomization in intubated or tracheotomized patients
GB8407359D0 (en) Catheter for administering oxygen
GB8912373D0 (en) Medicament for various skin and ulcer disorders
AU3406389A (en) Synergistic combinations of beta-mimetic compounds and PAF-antagonists and their use as therapeutic agents
AU2584788A (en) Medicament with antiemetic action
AU612267B2 (en) Medicaments
IE883395L (en) Medicament with antiemetic action